1. China Stocks

  2. •

    Health technology

  3. •

    Biotechnology
AIM Vaccine Co., Ltd. Class H

AIM Vaccine Co., Ltd. Class H

HHKEX:6660
1.51
HKD
+0.00
(-0.33%)
2.04BMarket Cap
Apr 01Next Earn
AIM Vaccine Co., Ltd. Class H
HKEX:6660
(Hong Kong Exchange)

Recent

price

1.51

P/E

ratio

- -

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
TTM
CNY
0.79
1.35
1.3
1.05
0.98
1.06
0.95
- -
Revenue per Share
0.1
0.31
-0.57
-0.27
-1.07
-0.23
-0.55
- -
Basic EPS, GAAP
-0.02
-0.34
-0.87
-0.8
-0.39
-0.11
-0.14
- -
Free Cash Flow per Basic Share
0.07
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
1.27
2.83
4.04
4.1
3.01
2.78
2.25
2.15
Book Value per Share
0.76
2.34
1.83
1.85
2.12
1.74
1.28
1.16
Tangible Book Value per Share
1,210
1,210
1,210
1,203
1,211
1,211
1,224
1,227
Basic Weighted Avg Shares
952
1,638
1,570
1,264
1,187
1,285
1,166
- -
Sales/Revenue/Turnover
17.62
29.62
-38.43
-30.15
-37.95
-16.41
-16.47
- -
Operating Margin (%)
109
128
144
166
175
172
158
- -
Depreciation Expense
117
379
-693
-320
-1,301
-277
-675
- -
Net Income, GAAP
23.57
17.59
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
12.34
23.16
-44.12
-25.28
-109.56
-21.57
-57.95
- -
Profit Margin (%)
155
1,307
789
299
-119
-703
-1,050
-1,201
Working Capital
51
47
226
369
569
434
357
313
LT Debt
1,618
3,422
5,699
5,861
3,890
3,611
2,937
2,807
Total Equity
- -
13.95
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
13.28
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
15.29
-16.66
-6.49
-30.25
-7.91
-22.06
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
1,337
1,399
1,458
LT Borrowings
438
355
309
LT Finance Leases
4
2
4
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,227
1,227
1,227
Market Capitalization
4,186
3,538
1,762

Working Capital

CNY

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
2,214
2,043
1,851
Cash, Cash Equivalents & STI
402
356
183
Accounts Receivable, Net
1,223
1,242
1,170
Inventories
434
347
370
Total Current Liabilities
3,026
3,093
3,052
Payables & Accruals
- -
- -
- -
ST Debt
1,337
1,399
1,458
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
1.99%
-18.68%
Free Cash Flow
- -
9.03%
23.23%
Net Income, GAAP
- -
7.1%
143.64%
Sales/Revenue/Turnover
- -
-6.15%
-9.29%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
1,285
2025
- -
- -
1,166
2026
- -
- -
- -

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.23
2025
- -
- -
-0.55
2026
- -
- -
- -

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
AIM Vaccine Co., Ltd. (6660.HK) engages in the research, development, manufacturing, and commercialization of human vaccines across China and select international markets, operating a full industrial chain with five validated vaccine technology platforms. Founded through acquisitions dating back to 2004 and restructured in 2020 with headquarters in Beijing, China, the company offers eight commercialized products targeting six diseases, including recombinant hepatitis B vaccine (Hansenula polymorpha, AIM Hanxin), freeze-dried human rabies vaccine (Vero cell, Rong'an Bio), inactivated hepatitis A vaccine (human diploid cell, AIM Kanghuai), live attenuated mumps vaccine (AIM Weixin), bivalent inactivated haemorrhagic fever with renal syndrome vaccine (Vero cell, AIM Weixin), and ACYW135 meningococcal polysaccharide vaccine (MPSV4, AIM Weixin); its subsidiaries encompass four wholly-owned manufacturing entities and three research institutes, with products distributed to 31 Chinese provinces and exported to regions such as Egypt, Pakistan, Southeast Asia, Africa, South America, and the Middle East. Recent developments include the 2024 Phase III completion and production license for the iterative serum-free rabies vaccine with market registration application accepted by China's NMPA in April 2025, alongside clinical trial approvals in 2025 for iterative-process highly-effective human diploid rabies vaccine, mRNA respiratory syncytial virus vaccine and mRNA herpes zoster vaccine by both U.S. FDA and China's NMPA, Phase III completion for 13-valent pneumococcal conjugate vaccine (PCV13) with marketing application submitted, full integration of DeepSeek AI across operations in February 2025 for lifecycle efficiency gains, and a narrowed net loss of 85-87% to RMB250-290 million on RMB1.25-1.3 billion revenue for 2024. The pipeline features 21 innovative vaccines for 13 diseases covering global top-10 categories, such as tetravalent meningococcal conjugate vaccine (MCV4), PCV13/PCV20/pneumococcal polysaccharide vaccines, mRNA COVID-19 variants, DTP combinations, influenza vaccines (MDCK cells), and EV71-CA16 bivalent hand-foot-mouth disease vaccine.